We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
- Authors
Assawakosri, Suvichada; Kanokudom, Sitthichai; Suntronwong, Nungruthai; Auphimai, Chompoonut; Nilyanimit, Pornjarim; Vichaiwattana, Preeyaporn; Thongmee, Thanunrat; Duangchinda, Thaneeya; Chantima, Warangkana; Pakchotanon, Pattarakul; Srimuan, Donchida; Thatsanatorn, Thaksaporn; Klinfueng, Sirapa; Yorsaeng, Ritthideach; Sudhinaraset, Natthinee; Wanlapakorn, Nasamon; Mongkolsapaya, Juthathip; Honsawek, Sittisak; Poovorawan, Yong
- Abstract
<bold>Background: </bold>The use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) against SARS-CoV-2 is implemented worldwide. However, waning immunity and breakthrough infections have been observed. Therefore, we hypothesized that the heterologous booster might improve the protection against the delta and omicron variants.<bold>Methods: </bold>A total of 224 individuals who completed the 2-dose CoronaVac for 6 months were included. We studied reactogenicity and immunogenicity after a heterologous booster with the inactivated vaccine (BBIBP), the viral vector vaccine (AZD1222), and the messenger ribonucleic acid (mRNA) vaccine (both BNT162B2 and mRNA-1273). We also determined immunogenicity at 3- and 6-month boosting intervals.<bold>Results: </bold>The solicited adverse events were mild to moderate and well tolerated. Total receptor binding domain (RBD) immunoglobulin (Ig), anti-RBD IgG, focus reduction neutralization test (FRNT50) against delta and omicron variants, and T-cell response were highest in the mRNA-1273 group followed by the BNT162b2, AZD1222, and BBIBP groups, respectively. We also witnessed a higher total Ig anti-RBD in the long-interval than in the short-interval group.<bold>Conclusions: </bold>All 4 booster vaccines significantly increased binding and neutralizing antibodies in individuals immunized with 2 doses of CoronaVac. The present evidence may benefit vaccine strategies to thwart variants of concern, including the omicron variant.
- Publication
Journal of Infectious Diseases, 2022, Vol 226, Issue 8, p1372
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1093/infdis/jiac092